Wugen
wugen.com
Regenerative Medicine
Cell & Gene Therapy
Claim pageClaim
Follow
Overview
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$259M
3 rounds on record
Latest round
$123.3M
Venture round · Aug 2025 · 14 mo ago
Backers
1
Aisling Capital
The money's age
Due for its next round
14 months since the last round · not hiring
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Aug 22, 2025
Raised a round Venture round $123.3M · SEC Form D
Jul 9, 2021
Raised a round Venture round $98.5M · SEC Form D
Apr 13, 2020
Raised a round Venture round $37.2M · SEC Form D
2018
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Aug 2025 | $123.3M | — | SEC Form D |
| Venture round | Jul 2021 | $98.5M | — | SEC Form D |
| Venture round | Apr 2020 | $37.2M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Wugen, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Daniel KempExecutive Officer, DirectorSEC Form D
Ayman KabakibiExecutive OfficerSEC Form D
Jan DavidsonExecutive OfficerSEC Form D
Matthew CooperExecutive OfficerSEC Form D
Cherry ThomasExecutive OfficerSEC Form D
Kumar SrinivasanExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Aisling Capital Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Developing next-generation cell therapies utilizing engineered biomaterial technologies.
We transform the way cell therapies are manufactured to enable affordable advanced treatments for all.
Exthymic is an early-stage deep-tech startup that develops point-of-care manufacturing systems for patient-specific cell therapies. Its…
Arsenal Biosciences, Inc. is a clinical stage, programmable cell therapy company focused on solid tumor cell therapies to defeat cancer.
Building programmable in vivo immune-cell therapies across oncology and autoimmune disease.
About Us Cell Therapies for Life-Threatening Diseases LyGenesis, Inc. is a clinical-stage cell therapy company that transforms a patient's…
Overview
Wugen is now Allotera A new era of Allogeneic T-Cell Therapies Continue to Allotera If you have any questions please contacts us at [email protected] Countdown Timer.
People
Daniel Kemp
Executive Officer, Director
Ayman Kabakibi
Executive Officer
Jan Davidson
Executive Officer
Matthew Cooper
Executive Officer
Cherry Thomas
Executive Officer
Kumar Srinivasan
Executive Officer, Director
Keith Vendola
Executive Officer
Bali Muralidhar
Director
John McKearn
Director
Bosun Hau
Director
Peter Kiener
Director
Kevin Li
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Saint Louis
United States
HQ